Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVS NASDAQ:NUAI NASDAQ:USAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$12.41-0.7%$14.48$3.55▼$26.95$1.05B0.941.67 million shs3.40 million shsNUAINew Era Energy & Digital$4.77+2.6%$4.45$0.32▼$9.44$471M1.236.02 million shs6.99 million shsUSARUSA Rare Earth$28.01-0.6%$21.15$8.00▼$43.98$6.29B2.3817.16 million shs15.09 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals-0.72%-1.59%-13.94%-32.04%+228.31%NUAINew Era Energy & Digital+2.58%+7.67%+29.27%+4.15%+476,999,900.00%USARUSA Rare Earth-0.64%+10.71%+27.14%+48.20%+236.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$12.41-0.7%$14.48$3.55▼$26.95$1.05B0.941.67 million shs3.40 million shsNUAINew Era Energy & Digital$4.77+2.6%$4.45$0.32▼$9.44$471M1.236.02 million shs6.99 million shsUSARUSA Rare Earth$28.01-0.6%$21.15$8.00▼$43.98$6.29B2.3817.16 million shs15.09 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals-0.72%-1.59%-13.94%-32.04%+228.31%NUAINew Era Energy & Digital+2.58%+7.67%+29.27%+4.15%+476,999,900.00%USARUSA Rare Earth-0.64%+10.71%+27.14%+48.20%+236.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 2.71Moderate Buy$33.33168.60% UpsideNUAINew Era Energy & Digital 2.50Moderate Buy$9.80105.45% UpsideUSARUSA Rare Earth 2.78Moderate Buy$35.4026.38% UpsideCurrent Analyst Ratings BreakdownLatest CRVS, NUAI, and USAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026NUAINew Era Energy & Digital Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026USARUSA Rare Earth Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/14/2026USARUSA Rare Earth Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $35.005/12/2026USARUSA Rare Earth WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$29.00 ➝ $35.004/29/2026CRVSCorvus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/23/2026USARUSA Rare Earth Northland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$45.004/21/2026USARUSA Rare Earth Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $32.004/20/2026USARUSA Rare Earth Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$30.004/20/2026USARUSA Rare Earth WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$29.004/20/2026USARUSA Rare Earth WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$29.004/17/2026CRVSCorvus Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/A$0.13 per share98.61$2.86 per shareN/ANUAINew Era Energy & Digital$880K549.04N/AN/A$0.10 per share47.70USARUSA Rare Earth$7.34M851.00N/AN/A$8.42 per share3.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$15.28M-$0.52N/AN/AN/AN/A-38.92%-35.75%8/6/2026 (Estimated)NUAINew Era Energy & Digital-$29.59M-$0.98N/AN/AN/A-2,592.43%-687.58%-101.21%N/AUSARUSA Rare Earth-$297.56M-$3.92N/AN/AN/AN/A-15.39%-10.08%N/ALatest CRVS, NUAI, and USAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026NUAINew Era Energy & DigitalN/A-$0.16N/A-$0.16N/A$0.80 million5/13/2026Q1 2026USARUSA Rare Earth-$0.16-$0.12+$0.04-$0.34N/A$5.70 million5/7/2026Q1 2026CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/A3/30/2026Q4 2025USARUSA Rare Earth-$0.12-$0.19-$0.07-$0.40N/AN/A3/12/2026Q4 2025CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/A3/12/2026Q4 2025NUAINew Era Energy & DigitalN/A-$0.41N/A-$0.41N/A$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/ANUAINew Era Energy & DigitalN/AN/AN/AN/AN/AUSARUSA Rare EarthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A19.8119.81NUAINew Era Energy & DigitalN/A0.100.10USARUSA Rare EarthN/A36.2935.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%NUAINew Era Energy & Digital21.90%USARUSA Rare EarthN/AInsider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals19.70%NUAINew Era Energy & Digital4.07%USARUSA Rare Earth46.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3084.09 million67.52 millionOptionableNUAINew Era Energy & DigitalN/A101.29 million97.17 millionN/AUSARUSA Rare EarthN/A223.04 million119.10 millionN/ACRVS, NUAI, and USAR HeadlinesRecent News About These CompaniesMP Materials accuses USA Rare Earth of tech theftMay 29 at 1:10 PM | northernminer.comNUSA Rare Earth Magnet Production And Defense Role Draw Investor FocusMay 29 at 3:08 AM | finance.yahoo.comUSA Rare Earth’s Chief Global Policy Officer Gregory Bowman Appointed to Department of War’s Science, Technology and Innovation BoardMay 28 at 4:56 PM | finance.yahoo.comUSA Rare Earth's Chief Global Policy Officer Gregory Bowman Appointed to Department of War's Science, Technology and Innovation BoardMay 28 at 4:30 PM | globenewswire.comUSAR vs. MP: Which Rare-Earth Stock Has an Edge Right Now?May 28 at 1:01 PM | zacks.comAtlas Lithium (NASDAQ:ATLX) & USA Rare Earth (NASDAQ:USAR) Financial AnalysisMay 28 at 4:41 AM | americanbankingnews.comMP Materials sues USA Rare Earth over alleged magnet technology theftMay 27 at 10:49 PM | msn.comChina Keeps Rare Earth Pressure on Washington After Trump SummitMay 27 at 10:49 PM | finance.yahoo.comMP Materials accuses USA Rare Earth of magnet tech theftMay 27 at 12:47 PM | mining.comRising Costs & Expenses Pressure USAR: What's the Road Ahead?May 27 at 12:31 PM | zacks.comIf You Buy USA Rare Earth Right Now, Could It Make You a Millionaire?May 26, 2026 | fool.com‘Made in America’ Faces a $2 Trillion Reality CheckMay 26, 2026 | finance.yahoo.comHead-To-Head Survey: Mountain Province Diamonds (OTCMKTS:MPVDF) versus USA Rare Earth (NASDAQ:USAR)May 26, 2026 | americanbankingnews.comChina Against Everybody: The New Geopolitics of Rare Earth ElementsMay 24, 2026 | 247wallst.comUSA Rare Earth - Strategic Importance Does Not Guarantee Attractive Equity ReturnsMay 24, 2026 | seekingalpha.comA Look At USA Rare Earth (USAR) Valuation After Strong Share Price MomentumMay 23, 2026 | finance.yahoo.com3 Rare Earth Stocks That Win No Matter What China Does Next...May 23, 2026 | marketbeat.comUSA Rare Earth selected for up to $19M in Department of Energy fundingMay 22, 2026 | seekingalpha.comUSA Rare Earth, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 21, 2026 | seekingalpha.comUSA Rare Earth stock jumps as DOE funding fuels growth optimismMay 21, 2026 | invezz.comIUSA Rare Earth Selected for U.S. Department of Energy Funding Under Critical Materials Innovation ProgramMay 21, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 20263 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 2026USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal LoomsBy Leo Miller | May 20, 2026CRVS, NUAI, and USAR Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$12.41 -0.09 (-0.72%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$12.54 +0.13 (+1.01%) As of 05/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.New Era Energy & Digital NASDAQ:NUAI$4.77 +0.12 (+2.58%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$4.75 -0.02 (-0.40%) As of 05/29/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.New Era Energy & Digital, Inc., operates as an exploration and production platform, engages in the exploration, development, and production of helium, oil and natural gas, and natural gas liquids in the United States. The company owns and operates a portfolio of approximately 137,000 acres in Southeast New Mexico. Its flagship Pecos Slope Field covering an area of 1893 square kilometers located 20 miles north of Roswell, New Mexico. It serves Tier 2 gas companies and balloon gas distributors. The company was formerly known as New Era Helium, Inc. and changed its name to New Era Energy & Digital, Inc. in August 2025. New Era Energy & Digital, Inc. is based in Midland, Texas.USA Rare Earth NASDAQ:USAR$28.01 -0.18 (-0.64%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$27.71 -0.30 (-1.08%) As of 05/29/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
